Cutaneous mucormycosis by
Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report.
Med Mycol Case Rep 2019;
26:42-43. [PMID:
31667060 PMCID:
PMC6812037 DOI:
10.1016/j.mmcr.2019.10.002]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2019] [Revised: 09/22/2019] [Accepted: 10/02/2019] [Indexed: 11/17/2022] Open
Abstract
Mucormycosis are a group of infections that affect principally immunocompromised host and have a high mortality. Liposomal amphotericin B is the first-line treatment with combined surgical removal of the infectious focus. We report the case of 67-year-old man with idiopathic granulocytic aplasia and a cutaneous lesion caused by Rhizopus arrhizus treated with isavuconazole. Its safety profile and spectrum of activity make it an important therapeutic option.
Collapse